Diabetic cardiomyopathy(DCM)is a major cause of heart failure in diabetic patients.It progresses asymptomatically prior to the onset of severe cardiac symptoms[1];therefore,elucidating the underlying mechanisms of DCM...Diabetic cardiomyopathy(DCM)is a major cause of heart failure in diabetic patients.It progresses asymptomatically prior to the onset of severe cardiac symptoms[1];therefore,elucidating the underlying mechanisms of DCM is critical to providing early treatment options.This commentary elaborates on the findings of Jiang et al.[2],who investigated the role of adipokine hormone,Adipsin,as a cardioprotective factor in DCM.We provide an exposition and alternative treatment considerations,like Fisetin,and discuss the potential of investigating other cellular targets implicated in cardiac dysfunction,like the interleukin-1 receptor-associated kinaselike 2(Irak2)protein[3]and protein kinase R[4].展开更多
Diabetic cardiomyopathy is a disorder of the cardiac muscle that affects patients with diabetes.The exact mechanisms underlying diabetic cardiomyopathy are mostly unknown,but several factors have been implicated in th...Diabetic cardiomyopathy is a disorder of the cardiac muscle that affects patients with diabetes.The exact mechanisms underlying diabetic cardiomyopathy are mostly unknown,but several factors have been implicated in the pathogenesis of the disease and its progression towards heart failure,including endothelial dysfunction,autonomic neuropathy,metabolic alterations,oxidative stress,and alterations in ion homeostasis,especially calcium transients[1].In Military Medical Research,Jiang et al.[2]sought to determine the functional role of complement factor D(Adipsin)in the pathophysiology of diabetic cardiomyopathy.展开更多
基金supported by the Office of Naval Research Grant(N00014-22-1-2184)。
文摘Diabetic cardiomyopathy(DCM)is a major cause of heart failure in diabetic patients.It progresses asymptomatically prior to the onset of severe cardiac symptoms[1];therefore,elucidating the underlying mechanisms of DCM is critical to providing early treatment options.This commentary elaborates on the findings of Jiang et al.[2],who investigated the role of adipokine hormone,Adipsin,as a cardioprotective factor in DCM.We provide an exposition and alternative treatment considerations,like Fisetin,and discuss the potential of investigating other cellular targets implicated in cardiac dysfunction,like the interleukin-1 receptor-associated kinaselike 2(Irak2)protein[3]and protein kinase R[4].
基金National Institutes of Health(NIH):National Heart,Lung,and Blood Institute(NHLBI:R01-HL164772,R01-HL159062,R01-HL146691,T32-HL144456)National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK:R01-DK123259,R01-DK033823)+2 种基金National Center for Advancing Translational Sciences(NCATS:UL1-TR002556-06,UM1-TR004400)(to Gaetano Santulli)Diabetes Action Research and Education Foundation(to Gaetano Santulli)Monique Weill-Caulier and Irma T.Hirschl Trusts(to Gaetano Santulli).
文摘Diabetic cardiomyopathy is a disorder of the cardiac muscle that affects patients with diabetes.The exact mechanisms underlying diabetic cardiomyopathy are mostly unknown,but several factors have been implicated in the pathogenesis of the disease and its progression towards heart failure,including endothelial dysfunction,autonomic neuropathy,metabolic alterations,oxidative stress,and alterations in ion homeostasis,especially calcium transients[1].In Military Medical Research,Jiang et al.[2]sought to determine the functional role of complement factor D(Adipsin)in the pathophysiology of diabetic cardiomyopathy.
